Bwxt stock hits 52-week low at 146.1 USD

BWX Technologies (BWXT) is expanding its nuclear services through a new Canadian lab management role via a joint venture. The contract began in December 2025, complementing BWXT's broader strategy. The Kinectrics acquisition, completed in May 2025, is key to this expansion. BWXT's commercial revenues grew 62.8% YoY to $853.1M in 2025, with Kinectrics contributing $231M. Analysts expect EPS growth of 18.45% and 10.73% for 2026 and 2027, respectively.

Jefferies initiated coverage of Cameco (CCJ) and BWXT (BWXT) with 'Buy' ratings, setting price targets of $138 and $181 respectively, citing strong long-term prospects in nuclear energy. CCJ, a major uranium producer, and BWXT, a nuclear reactor provider, are positioned to benefit from global and U.S. initiatives to expand nuclear capacity. Both companies face risks, including uranium price volatility for CCJ and execution challenges for BWXT.

BWX Technologies (NYSE: BWXT) is the lowest-valued nuclear stock despite its monopoly in supplying nuclear reactors and fuel to the U.S. Navy. Its Q2 revenue rose 18% YoY to $901.6M, with EPS up 5% to $1.07. The company has an $8.6B backlog and raised its yearly revenue guidance to $3.8B. BWX also expanded into commercial markets, with Q2 commercial revenue up 72% YoY to $303M.

Wells Fargo upgraded BWX Technologies (BWXT) to Equal Weight, lowering its target price to $170. The company reported Q2 2026 revenue of $901.6M, up from $764M last year, with adjusted EPS of $1.07. BWXT raised its full-year revenue guidance to $3.8B and adjusted EPS guidance to $4.70-$4.80. The stock is down 11.89% year-to-date. Management highlighted growth in commercial operations, while analysts noted risks related to revenue mix and leverage.

Parsons (PSN) reported flat Q2 revenue of $1.58B, missing estimates, and lowered full-year guidance, causing its stock to drop 26.3%. BWX (BWXT) reported $901.6M revenue, up 18%, meeting expectations and beating EBITDA guidance. RTX (RTX) reported $24.71B revenue, up 14.5%, beating expectations and raising EPS guidance. The stock is up 3.2% since reporting.

Jefferies initiated coverage of Cameco (CCJ) and BWX Technologies (BWXT) with Buy ratings, setting price targets at $138 and $181 respectively. The firm expects strong demand in the global nuclear industry, benefiting both companies. CCJ and BWXT shares rose 3.7% and 2.9% on the news.